ReviewCureus2026
A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is an increasingly growing public health issue affecting a substantial proportion of the population in the United States. This condition increases the risk for multiple disease processes, including cardiometabolic disorders, osteoarthritis, gout, respiratory issues, reproductive problems, and some cancers. Glucagon-like peptide-1 (GLP-1) receptor agonists got their first US Food and Drug Administration (FDA) approval in 2005 in the form of exenatide for type 2 diabetes mellitus (T2DM) management. Thereafter, GLP-1 analogs have been increasingly studied as a noninvasive strategy for weight reduction, and they transitioned from diabetes-only therapies to weight management with the approval of once-daily liraglutide prior to weekly semaglutide formulation in 2021. In essence, GLP-1 receptor agonists have emerged as a promising drug for long-lasting weight reduction and blood glucose control for patients with or without type 2 diabetes mellitus, surpassing traditional methods such as lifestyle changes and bariatric surgery. Oral Wegovy (Rybelsus) was approved for T2DM management in 2020; however, it is approved for weight loss after the recent publication of Oral Semaglutide in Adults with Overweight or Obesity (OASIS). This literature review will discuss and summarize weight loss results from OASIS trials 1, 2, 3, and 4. The OASIS 1 and 2 trials compared the therapeutic efficacy and clinical safety profile of once-daily oral semaglutide 50 mg versus placebo on overweight and obese participants without T2DM and both with and without T2DM, respectively. The OASIS 3 trial assessed the therapeutic efficacy and clinical safety profile of once-daily oral semaglutide 50 mg versus placebo in 200 Chinese adults who were obese and overweight with one or more weight-related comorbidities, including T2DM. The OASIS 4 trial evaluated the safety and effectiveness of once-daily semaglutide 25 mg in obese and overweight patients without T2DM. Clinical trial data and relevant literature were retrieved through database searches of the National Center for Biotechnology Information and ClinicalTrials.gov. The OASIS 1, 2, and 4 demonstrated that oral semaglutide has superior efficacy compared to placebo in body weight loss, which helped secure FDA approval for oral Wegovy. Though OASIS 3 is registered in clinical trials, the results of OASIS 3 have not been published in a peer-reviewed journal yet.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.